Attention People Suffering from Black Lung Disease:
If you are suffering from BlackLung Disease we encourage you to try our Black Lung Disease package. Users that have started with these products have reported results almost immediately. With a 95% success rate for people using the Black Lung Disease product package, users are reporting that even within in the first 2 weeks they are seeing an improvement in breathing, less mucus build up, and an increase in their energy levels. If you have had Black Lung Disease for years, or if you have just been diagnosed, the products we offer will have a positive impact in your fight against Pulmonary Fibrosis. Don't just take our word for it, Janice from Sacramento, CA writes:
"Pivotal Health, I am a 63 yr old female that was diagnosed with Pulmonary Fibrosis about a year and a half ago. Not knowing what to do I took my doctors advice and I did exactly what he said to do. After one year he explained that my condition was getting worse and that I now need to be on oxygen. As you can imagine I was very frustrated to learn that I was not getting any better. Around June my son decided to see what my other options were, after a lot of research on the internet I came across pivotal health's website and their pulmonary fibrosis information. I called pivotal health after looking around the internet to see what other people dealing with pulmonary fibrosis were doing to stop this condition. As you may know there isn't many options available for people with my condition. I spoke with Troy at Pivotal Health and he was very knowledgeable and very helpful. He told me that he talks with Pulmonary Fibrosis patients everyday, and that the product package they offer is 95% successful to people taking it. I must say after after 2 weeks on these products I couldn't believe I was able to take deep breaths again, my mucus is almost completely gone and I have cut down on the use of my oxygen machine considerably. I have know been on the products coming up on 3 months I no longer use oxygen at all, my doctor could not believe my last chest scan, that showed my scar tissue in my lungs was reduced by almost 60%. My advice to anyone out there that is looking for hope and feels like they don't have any more options, is to call Pivotal Health. That one call changed my life.
Thank you so very much, Janice 9/4/09
To Pivotal Health & Troy Oct 6, 2009
We heard about Serracor-NK from a friend who had a heart attack and was told he would need bypass surgery.
He did research and found this product he started taking it and when he went back to the cardiologist in 6 months he was told that they could not find any blockage in his heart or his heart arteries. He has continued to take this product and says he will keep taking it. Our experience with this product is that Cody has had triple bypass surgery and had high blood pressure. When Tony told Cody and I about this product we came home and ordered some and Cody has been taking it for 5 months in July we went to see Codys cardiologist and he told him that he was doing well and to keep doing what ever he was doing because it was working. His blood pressure has gone down and he has recently also had blood work done and his numbers are all normal which they were not last time they were done. We feel that this is due in large to him taking this product. He will be continuing to take it long term. Thanks Pivotal Health for a great product.
Pulmonary Testimonial September 15, 2009
I was diagnosed with pulmonary fibrosis over 4 years ago and my doctor gave me 3 years to live. I was coughing constantly and I had a lot of inflammation. I decided to not give up so, I went online and found an enzyme with the sebkinase blend in it. I began taking it and after 1 month my coughing was pretty much gone and I started improving more and more everyday. I have now been taking the sebkinase blend for over 4 years and my doctors are stumped that I show very little evidence of my pulmonary fibroses and I feel great! I wanted to do this testimonial for Troy at Pivotal Health in hopes that this will help others with pulmonary fibrosis and to let them know that there is help available. I take Serracor NK everyday and I will continue to do so for the rest of my life. Don't give up hope this product will help you.
A chronic occupational lung disease contracted by the prolonged breathing of coal mine dust. The silica and carbon in the coal dust cause black lung disease. About one of every 20 miners studied in the US has X-ray evidence of black lung disease, a form of pneumoconiosis.
In its early stages, called simple pneumoconiosis, the disease does not prevent the miner from working or carrying on most normal activities. In some miners, the disease never becomes more severe. In other miners, the disease progresses from simple to complicated pneumoconiosis, a condition also called progressive massive fibrosis. Pneumoconiosis is not reversible. There is no specific treatment.
Black lung disease has gone by many names, including anthracosis, black lung, black spittle, coal worker's pneumoconiosis, miner's asthma, and silicosis.
The term miner's asthma was first used in 1822. The cause of the spitting, coughing, and breathlessness in coal miners was unknown, so doctors used the word asthma to identify the condition. Later, silicosis became known as the disease producing breathlessness in miners who had worked where silica was thought to be in the coal mine dust.
While black spittle and black pigmentation of the lung were observed in European coal miners during the 17th and 18th centuries, it was not until 1831 that the term black lung was introduced; it was used to describe the lungs of a Scottish coal miner. From then until the end of the nineteenth century, coal mine dust was generally acknowledged in Europe to be the cause of the black lungs and the shortness of breath occurring among coal miners. In 1880 emile Zola, in his famous novel about French coal miners, Germinal, wrote eloquently about the devastating effect of black lung.
Coal workers' pneumoconiosis was the term British investigators used for the first time in 1942 to identify a type of dust disease observed in coal miners. The following year this disease, as distinct from, and in addition to, classical silicosis, became compensable in the United Kingdom. Like all occupational diseases, black lung is man-made and can be prevented.
There is new hope for people suffering from Black Lung Disease. Serracor-NK a systemic enzyme formula is designed to breakdown and dissolves scar tissue and mucus along with boosting the body�?s immune defenses.
Serracor-NK and Black Lung Disease
Serracor-NK and Black Lung Disease
Black lung disease is a combination of high amounts of scar tissue build up in the lungs and toxins and debris that are stored in the lining of the lungs that are inhaled in over the many years a miner works in very toxic and damaging conditions. Almost all miners contract black lung disease in their lifetime. Over half of those people bodies are able to fight back against this condition and it will not become a life threatening condition. The other 30-40% of miners our left with a lifetime battle against this conditions side effects which include difficulty breathing, low oxygen uptake, pneumonia, mucus, severe coughing and wheezing and infection in the lungs.
Serracor-NK is showing promising results as over 95% of users taking Serracor-NK for Black Lung Disease are able to improve breathing and decrease mucus and film in 30 days. After the 30 day period suffers of this disease are dramatically reducing the scar tissue in the lungs and even starting to repair damaged tissue in the lining of the lungs which is resulting in the body being able to increase the amount of oxygen in the blood. Serracor-NK will increase the breakdown of the toxins built up in the lungs which will help users fight off bacteria’s and virus’s that people suffering from black lung are so easily plagued by.
How can Serracor-NK can help for Black lung Disease?
Serracor-NK is a gaining popularity and becoming a promising supplement for people suffering from the harmful and life threatening effects of Pulmonary Fibrosis. Serracor-NK has encouraging outcome for people suffering from Pulmonary Fibrosis. The combination of Serrapeptase and Nattokinase in Serracor-NK are formulated to break up fibrinogen and lower the body’s anti-inflammatory response. The use of systemic enzymes for Pulmonary Fibrosis is a new approach to combat the fibrin build up in the arterial lining within the lung walls. By reducing the fibrin levels within the lungs a synergistic effect is also created by the Serracor-NK formula, improve immune function. By removing the fibrin from the lungs your body’s inflammation marker will drop resulting in improved immune function which in turn allows the body’s natural healing process to begin. A secondary function on Serracor-NK is the decreased amount of mucus to be harnessed in the lungs. As mucus levels drop so will the bacteria and infection within the lung membranes. Fibrin being a major cause to reduction of airflow and by reducing the infection of bacteria in the lungs, users will start to have an improvement of airflow, reduction of mucus, improved energy and an overall improvement in their body’s immune response.
Serracor-NK is an important step in the fight against Black lung Disease. Users should always consult with a doctor before taking any supplement and also taking prescribed pharmaceuticals. Serracor-NK should not be taken with any blood thinning medication. Serracor-NK does thin the blood and users should always discontinue the use of Serracor-NK if your are taking any blood thinning medications.9
Serracor-Nk Clinical Information
Research and Clinical Studies done on the main ingredients in Serracor-NK
The research behind Enzyme Therapy for Black Lung Disease?
Serrapeptase has been in use since 1979. Since then the effacous anti-inflammatory response with the use of Serrapeptase has been shown not only as new way to eliminate fibrin or fibrous formations in the body systemically but is showing promising results for Chronic inflammation in the lungs along with the dispelling of mucus in the lining of the arterial walls in the lungs. Studies have shown the positive effects of Serrrapeptase for the use of Pulmonary Fibrosis.
Serrapeptase Study #1
Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease.
OBJECTIVES: The proteolytic enzyme serrapeptase (SER) is widely used in clinical practice in Japan. We investigated the effect of SER on sputum properties and symptoms in patients with chronic airway diseases. METHODS: This study was an open-labelled trial with a non-treatment control group. Patients were randomly assigned to oral treatment with (n = 15) and without (n = 14) SER 30 mg/day for 4 weeks. Patients collected sputum samples for about 4 h in the morning on the day the trial began and 4 weeks later. We measured the amount of sputum by weighing. Part of each sputum sample was weighed and then completely dried and reweighed. The percentage solid component, viscosity and elasticity of the sputum were measured. Mucociliary transportability index was measured using ciliated bovine trachea ex vivo. Sputum smears were also prepared to count sputum neutrophils. Patients' symptoms were assessed by a questionnaire that used a visual analogue scale. RESULTS: After 4 weeks of SER treatment, sputum weight in the morning, percentage solid component, viscosity and elasticity of sputum, sputum neutrophil count, frequency of coughing and frequency of expectoration significantly decreased. The mean mucociliary transportability index increased from 13.3 +/- 1.8 to 24.4 +/- 2.5 (P = 0.0103). CONCLUSIONS: SER may exert a beneficial effect on mucus clearance by reducing neutrophil numbers and altering the viscoelasticity of sputum in patients with chronic airway diseases.3
Serrapeptase Study #2
Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo.
The efficacy and tolerability of Serratia peptidase were evaluated in a multicentre, double-blind, placebo-controlled study of 193 subjects suffering from acute or chronic ear, nose or throat disorders. Treatment lasted 7-8 days, with the drug or placebo being administered at a rate of two tablets three times a day. After 3-4 days' treatment, significant symptom regression was observed in peptidase-treated patients. There was also a significant reduction in symptoms after 7-8 days for patients in both treatment groups but the response was more marked in those patients receiving the active drug. Statistical comparison between the two groups confirmed the greater efficacy and rapid action of the peptidase against all the symptoms examined at both stages. Tolerance was found to be very good and similar for both groups. It is concluded that Serratia peptidase has anti-inflammatory, anti-oedemic and fibrinolytic activity and acts rapidly on localized inflammation.4
Another effacious systemic enzyme Nattokinasehas been used by Japanese Pharmaceutical companies for anti-thrombosus and blood anti-coagulation. Nattokinase like Serrapeptase has had a good amount of clinical studies behind it, to prove not only is Nattokinase effective for thinning the blood and reversing the formation of blood clots but it has shown to be one of the strongest fibrinolytic activity systemically in the blood stream.
The use of Nattokinase for Black Lung Disease
Another effacious systemic enzyme Nattokinase has been used by Japanese Pharmaceutical companies for anti-thrombosus and blood anti-coagulation. Nattokinase like Serrapeptase has had a good amount of clinical studies behind it, to prove not only is Nattokinase effective for thinning the blood and reversing the formation of blood clots but it has shown to be one of the strongest fibrinolytic activity systemically in the blood stream.
Nattokinase Study #1
Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects
Nattokinase, a serine proteinase from Bacillus subtilis, is considered to be one of the most active functional ingredients found in natto. In this study, we hypothesized that nattokinase could reduce certain factors of blood clotting and lipids that are associated with an increase risk for cardiovascular disease (CVD). Thus, an open-label, self-controlled clinical trial was conducted on subjects of the following groups: healthy volunteers (Healthy Group), patients with cardiovascular risk factors (Cardiovascular Group), and patients undergoing dialysis (Dialysis Group). All subjects ingested 2 capsules of nattokinase (2000 fibrinolysis units per capsule) daily orally for 2 months. The laboratory measurements were performed on the screening visit and, subsequently, regularly after the initiation of the study. The intent-to-treat analysis was performed on all 45 enrolled subjects. By use of mixed model analysis, a significant time effect, but not group effect, was observed in the change from baseline of fibrinogen (P = .003), factor VII (P < .001), and factor VIII (P < .001), suggesting that the plasma levels of the 3 coagulation factors continuously declined during intake; also, the extents of decrease were similar between groups. After 2 months of administration, fibrinogen, factor VII, and factor VIII decreased 9%, 14%, and 17%, respectively, for the Healthy Group; 7%, 13%, and 19%, respectively, for the Cardiovascular Group; and 10%, 7%, and 19%, respectively, for the Dialysis Group, whereas blood lipids were unaffected by nattokinase. No significant changes of uric acid or notable adverse events were observed in any of the subjects. In summary, this study showed that oral administration of nattokinase could be considered as a CVD nutraceutical by decreasing plasma levels of fibrinogen, factor VII, and factor VIII.5
Nattokinase Study #2
Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase.
The existence of a potent fibrinolytic enzyme (nattokinase, NK) in the traditional fermented food called 'natto', was reported by us previously. It was confirmed that oral administration of NK (or natto) produced a mild and frequent enhancement of the fibrinolytic activity in the plasma, as indicated by the fibrinolytic parameters, and the production of tissue plasminogen activator. NK capsules were also administered orally to dogs with experimentally induced thrombosis, and lysis of the thrombi was observed by angiography. The results obtained suggest that NK represents a possible drug for use not only in the treatment of embolism but also in the prevention of the disease, since NK has a proven safety and can be mass produced.6
Serracor-NK® is not recommended for women that are pregnant or nursing, as these groups have not been clinically tested. Anemic women with heavy periods should take Serracor-NK® with caution, as additional bleeding can occur.Do not take Serracor-NK® if your fibroids are causing immediate health concerns, or if you are currently taking blood thinning medication. As always consult with your doctor before taking Serracor-NK®.
As you begin to take Serracor-NK® toxins and other debris will be expelled from your system.We refer to this process as enzymatic detoxification. Symptoms such as fatigue, upset stomach, headaches, and diarrhea may occur. If at any point you start to feel ill you may be detoxifying too quickly. Decreasing your dosage for a more gradual and comfortable detoxification period is therefore recommended. It may take several days to completely cleanse the body of unwanted toxins. Enzymatic detoxification is only temporary, and in the most extreme cases may last up to a period of 14 days.
I have been using the Pulmonary Fibrosis Package # 5 for 4 weeks and I really feel more energy. I have improvement with my oxygenation and I feel a good reaction of my body. I now take a shower with confidents, cough less and my lungs now feel free. I have an oxygen measurer and I have improved from the 70's to the 80's. Thanks you Pivotal Health.
Toll Free USA 1-877-404-8804 / INT'L 1-602-404-3384
Pivotal Health Products Corp.
4727 E. Bell Road, Suite 45-447
Phoenix, AZ 85032-9339 Toll Free in USA 1-877-404-8804
International calls only 001-602-404-3384 Email: firstname.lastname@example.org
Do not take Serracor-NKif your are currently taking blood thinning medication. Serracor-NK is not recommended for women who are pregnant or nursing as these groups have not been clinically tested. As always, consult with your doctor before taking Serracor-NK.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. For all conditions or illnesses, see a healthcare professional for a full evaluation, diagnosis or treatment plan.